Objective: We aimed to investigate the associations between age at radical prostate cancer treatment and long-term global quality of life (QoL), physical function (PF), and treatment-related side effects.

Material and Methods: This single-center, cross-sectional study included men treated for localized pros-tate  cancer  with  robotic-assisted  radical  prostatectomy  (RARP)  or  external  beam  radiotherapy  (EBRT)  in  2014–2018.  Global  QoL  and  PF  were  assessed  by  the  European  Organisation  of  Research  and  Treatment  in Cancer Quality of life Questionnaire-C30 (QLQ-C30), side effects by the Expanded Prostate Cancer Index Composite  (EPIC-26).  Adjusted  linear  regression  models  were  estimated  to  assess  associations  between  age (continuous variable) at treatment and outcomes. QLQ-C30 scores were compared to normative data after dividing the cohort in two groups, <70 years and ≥70 years at treatment.

Results: Of 654 men included, 516 (79%) had undergone RARP, and 138 (21%) had undergone EBRT com-bined with androgen deprivation therapy for 93%. Mean time since treatment was 57 months. Median age at treatment was 68 (min–max 44–84) years. We found no statistically significant independent association between age at treatment and global QoL, PF or side effects, except for sexual function (regression coeffi-cient [RC] −0.77; p < 0.001) and hormonal/vitality (RC 0.30; p = 0.006) function. Mean QLQ-C30 scores were slightly  poorer  than  age-adjusted  normative  scores,  for  men  <70  years  (n  =  411)  as  well  as  for  men  ≥70  years (n = 243) at treatment, but the differences were not beyond clinical significance.

Conclusions: In this cohort of prostate cancer survivors, age at treatment had little impact on long-term QoL and function. Due to the cross-sectional design, short term impact or variation over time cannot be ruled out.

Tilgang til artikkelen